Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The hemagglutinin (HA) antigen of Influenza A virus, specifically the H1 subtype, is a surface glycoprotein essential for viral entry into host cells. It binds sialic acid-containing receptors on the host cell surface, facilitating viral attachment and entry. After endocytosis and exposure to low pH, conformational changes in the protein mediate fusion between the viral envelope and endosomal membrane. Variations in H1 influence host specificity and virulence. It contains major antigenic sites recognized by neutralizing antibodies.
Binding to sialic acid receptors on host cells, mediating viral entry and membrane fusion. Target of neutralizing antibodies that prevent these processes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Influenza A Virus Hemagglutinin Antigen (H1) (None).